Actualités

Assessing the risk of cervical neoplasia in the post-HPV vaccination era

Int J Cancer​2022 Sep 12.doi: 10.1002/ijc.34286

Weekly epidemiological record  -  Relevé épidémiologique hebdomadaire

Weekly Epidemiological record N° 24, 2022, 97, 261–276, 17 June 2022

Head-to-head comparison of bi- and nonavalent human papillomavirus vaccine-induced antibody responses

J Infect Dis​. 2022 May 10;jiac190. doi: 10.1093/infdis/jiac190

Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a clusterrandomised trial

BMJ Open​ . 2021 Dec 30;11(12):e050669. doi: 10.1136/bmjopen-2021-050669

HPV Vaccination and the Risk of Invasive Cervical Cancer

The New England Journal of Medicine 383;14 nejm.org October 1, 2020

Design and content validation of a survey questionnaire assessing the determinants of human papillomavirus (HPV) vaccine hesitancy in France: A reactive Delphi study

Elsevier Vaccine. 2020 Jul 25;S0264-410X(20)30943-9 | doi: 10.1016/j.vaccine.2020.07.027.

Vaccination  HPV universelle, garçons et filles 

Recommandations Haute Autorité de Santé (HAS décembre 2019)

Pour un dépistage et une vaccination unvierselle contre la papillomavirus

Appel des 50 : Académies, Collèges, Socités et Syndicaux médicaux

Communiqué de presse  20 mars 2019

Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancerin 181 countries, 2020-99 : a modelling study

www.thelancet.com - Published online February 19, 2019

Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15–26 Years of Age

2018 by the American College of Obstetricians and Gynecologists

Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017±2035: Example from Australia

 PLOS ONE | https://doi.org/10.1371/journal.pone.0185332 February 14, 2018

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

www.thelancet.com - Published online September 5, 2017

Nine-valent human papillomavirus vaccine: great science, but will it save lives?

www.thelancet.com - Published online September 5, 2017

Vaccination contre les infections à HPV et risque de maladies autoimmunes : une étude Cnamts/ANSM rassurante - Point d'information

ANSM/CNAMTS (13/09/2015)

Vaccins anti-HPV et risque de maladies autoimmunes : étude pharmacoépidémiologique

ANSM/CNAMTS (Rapport final, septembre 2015)

No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England

Vaccine (2017) 1729-1732 - Copyright 2017 Published by Elsevier Ltd.

Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs

Journal of Infectious Diseases Advance Access published (July 30, 2015)

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

The New England Journal of Medicine 372;8 nejm.org (February 19, 2015)

Safety of human papillomavirus vaccines: a review

Expert Opin. Drug Saf. (2015) 14(5) (February 24, 2015)

Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other Demyelinating Diseases of the Central Nervous System

JAMA. 2015;313(1):54-61 doi:10.1001/jama.2014.16946 (January 6, 2015)

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia

BMJ 2014;348:g1458 doi: 10.1136/bmj.g1458 (March 4,2014)

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States

JAMA January 6, 2015 Volume 313, Number 1

Safety of human papillomavirus vaccines: a review

Expert Opin. Drug Saf. (2015) 14(5) 

HPV “Coverage”

N. Engl J Med 372;8 nejm.org february 19, 2015  

The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon

BMJ 2014;348:g1458 doi: 10.1136/Expert Rev. Vaccines Early online, 1–12 (2014)

Avis d’experts (Europe et Australie)

Décembre 2013

Profil de sécurité des vaccins HPV, faut-il s'en inquiéter ?

Génésis - N°177 Février/mars 2014

Safety of Human Papillomavirus Vaccines: A Review

Springer International Publishing Switzerland 2013

Vaccins HPV : que font nos autorités de santé face à la crise ?

(12 décembre 2013, Le Quotidien du Médecin)

Prévention du cancer du col utérin (II) : vaccination HPV prophylactique, connaissances actuelles, modalités pratiques et nouveaux enjeux

Presse Med. 007; 36: 640 - 2007 Elsevier Masson

Prévention du cancer du col utérin (I) : apport du dépistage, récents progrès et perspectives

Presse Med. 2007; 36: 92-111 - 2006 Elsevier Masson

Vaccination HPV